These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38071551)

  • 21. Differential Interactions of Cytochrome P450 3A5 and 3A4 with Chemotherapeutic Agent-Vincristine: A Comparative Molecular Dynamics Study.
    Saba N; Bhuyan R; Nandy SK; Seal A
    Anticancer Agents Med Chem; 2015; 15(4):475-83. PubMed ID: 25634447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
    van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5.
    Niwa T; Murayama N; Emoto C; Yamazaki H
    Curr Drug Metab; 2008 Jan; 9(1):20-33. PubMed ID: 18220568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.
    Guilhaumou R; Solas C; Bourgarel-Rey V; Quaranta S; Rome A; Simon N; Lacarelle B; Andre N
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1633-8. PubMed ID: 21968951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Toxicity of Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma Pediatric Egyptian Patients.
    Shalaby N; Zaki HF; Badary OA; Kamal S; Nagy M; Makhlouf D; Elnashar A; Elnadi E; Abdelshafi SA; Abouelnaga S; Saber MM
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1391-1409. PubMed ID: 38680001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe Vincristine-induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study.
    Bosilkovska M; Ing Lorenzini K; Uppugunduri CR; Desmeules J; Daali Y; Escher M
    Clin Ther; 2016 Jan; 38(1):216-20. PubMed ID: 26565076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of breviscapine on CYP3A metabolic activity in healthy volunteers.
    Zhou X; Gao YY; Hu JY; Dong Y; Zhang HZ; Lai Y
    Eur J Clin Pharmacol; 2018 Jan; 74(1):37-44. PubMed ID: 28986606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
    Klees TM; Sheffels P; Dale O; Kharasch ED
    Drug Metab Dispos; 2005 Mar; 33(3):303-11. PubMed ID: 15557344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulatory and Inhibitory Effects of Steroid Hormones and Human Cytochrome P450 (CYP) 3A Inhibitors on Cortisol 6β-Hydroxylation Catalyzed by CYP3A Subfamilies.
    Niwa T; Tani M; Suzuki A; Murakami M
    Drug Metab Bioanal Lett; 2023; 16(2):73-80. PubMed ID: 37649294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
    Halama B; Hohmann N; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Clin Pharmacol Ther; 2013 Jun; 93(6):564-71. PubMed ID: 23511711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
    Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
    J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of the minor cytochrome P450 3A isoforms.
    Daly AK
    Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
    Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
    Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy in Children with Cancer: A Systematic Review and Meta-Analysis.
    Uittenboogaard A; Neutel CLG; Ket JCF; Njuguna F; Huitema ADR; Kaspers GJL; van de Velde ME
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: Effect of interleukin 6-induced suppression of the cytochrome P450 3A gene.
    Enokiya T; Nishikawa K; Hamada Y; Ikemura K; Sugimura Y; Okuda M
    Basic Clin Pharmacol Toxicol; 2021 Mar; 128(3):525-533. PubMed ID: 33248001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
    Sun JY; Xu ZJ; Sun F; Guo HL; Ding XS; Chen F; Xu J
    Curr Pharm Des; 2018; 24(24):2765-2773. PubMed ID: 30156148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5.
    Wang J; Buchman CD; Seetharaman J; Miller DJ; Huber AD; Wu J; Chai SC; Garcia-Maldonado E; Wright WC; Chenge J; Chen T
    J Am Chem Soc; 2021 Nov; 143(44):18467-18480. PubMed ID: 34648292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.
    Klees TM; Sheffels P; Thummel KE; Kharasch ED
    Anesthesiology; 2005 Mar; 102(3):550-6. PubMed ID: 15731592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
    Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
    Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
    J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.